TECH Insider: John L. Higgins Exercises Options; Holdings Now 65,236 Shares

Rhea-AI Filing Summary

John L. Higgins, a director of Bio-Techne (TECH), reported exercising stock options to acquire 5,040 shares of common stock on 08/07/2025 at an exercise price of $21.84 per share. After that transaction his reported beneficial ownership of common stock is 65,236 shares. The Form 4 lists a series of outstanding stock options held by Higgins with varying exercise prices ($21.84 to $128.81) and expiration dates ranging through 10/24/2034.

The filing also includes a disclosure that a grant made 10/24/2024 vests on the earlier of the one‑year anniversary of the grant or Bio‑Techne's 2025 annual meeting of shareholders. The form was signed by an attorney‑in‑fact acting on Higgins' behalf.

Positive

• Director acquired 5,040 shares by exercising options at an exercise price of $21.84 per share
• Beneficial ownership after the transaction: 65,236 shares
• Detailed listing of outstanding stock options with exercise prices and expiration dates through 10/24/2034
• Vesting condition for 10/24/2024 grant explicitly disclosed

Negative

• None.

Insights

Financial Analyst

TL;DR: Director exercised options, acquiring 5,040 shares and increasing beneficial ownership to 65,236 shares.

The transaction recorded is an option exercise (transaction code M) that resulted in the acquisition of 5,040 common shares at an exercise price of $21.84. Post‑transaction beneficial ownership is reported as 65,236 shares. Table II shows multiple remaining options with exercise prices from $21.84 to $128.81 and expirations out to 10/24/2034, indicating ongoing potential future dilution if exercised. The filing is a routine Section 16 disclosure of insider activity.

Corporate Governance Expert

TL;DR: Routine insider exercise and disclosure; vesting condition on a 2024 grant is explicitly noted.

The Form 4 documents a standard director option exercise and insider reporting. It explicitly states a vesting condition for an option grant dated 10/24/2024 (vesting on the earlier of the one‑year anniversary or the 2025 annual meeting). The form was submitted under power of attorney, with an attorney‑in‑fact signing on behalf of the reporting person. This filing provides clear, itemized disclosure of current option positions and post‑transaction common stock holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HIGGINS JOHN L

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		M		5,040	A	$21.84	65,236	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.84	08/07/2025		M			5,040	10/29/2016	10/28/2025	Common Stock	5,040	$0	0	D
Stock Option (Right to Buy)	$25.3							10/26/2017	10/26/2026	Common Stock	15,940		15,940	D
Stock Option (Right to Buy)	$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D
Stock Option (Right to Buy)	$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D
Stock Option (Right to Buy)	$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D
Stock Option (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Option (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Option (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Option (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Option (Right to Buy)	$68.37							(1)	10/24/2034	Common Stock	3,511		3,511	D

Explanation of Responses:

1. The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.

	/s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bio‑Techne (TECH) report for John L. Higgins?

The Form 4 reports that John L. Higgins exercised options to acquire 5,040 shares of Bio‑Techne common stock.

At what price were the 5,040 shares acquired by the director on the Form 4?

The 5,040 shares were acquired at an exercise price of $21.84 per share.

How many Bio‑Techne shares does John L. Higgins beneficially own after the reported transaction?

Following the reported transaction, Higgins' beneficial ownership is reported as 65,236 shares.

Does the Form 4 list other option holdings for John L. Higgins?

Yes. The filing lists multiple outstanding stock options with exercise prices from $21.84 to $128.81 and expirations through 10/24/2034.

Is there any special vesting condition disclosed in the filing?

Yes. The filing states that the option grant dated 10/24/2024 vests on the earlier of the one‑year anniversary of the grant or Bio‑Techne's 2025 annual meeting of shareholders.